Salute e Benessere
RNA-based Therapies Market to Reach USD 213.54 Billion by 2033, Driven by Rare Diseases, Oncology, and Advances in RNA Technologies | DataM Intelligence
However, the industry faces challenges such as Despite these restraints, opportunities are expanding in oncology, cardiometabolic disorders, immunology, and rare diseases, driven by innovations such as self-amplifying RNA and small activating RNA platforms.
in revenues. Pfizer, Moderna, and BioNTech continue to lead this space, expanding indications beyond infectious diseases into oncology and rare diseases.
generated approximately in 2024, with therapies from Sarepta and Biogen addressing neuromuscular and genetic disorders.
therapies, valued at , are growing rapidly, led by Alnylam Pharmaceuticals' expanding portfolio for metabolic and rare diseases.
, though still emerging, represented , with increasing clinical trial activity focused on rare genetic and hematologic disorders.
contributed , primarily in oncology and cardiovascular applications.
RNA therapeutics are increasingly used in precision oncology through mRNA vaccines and RNAi-based silencing of oncogenic pathways.
contributed , fueled by high-impact therapies for Duchenne muscular dystrophy, spinal muscular atrophy, and transthyretin amyloidosis.
remained significant, valued at , as mRNA vaccine platforms expand into influenza, RSV, and emerging pathogens.
, driven by ASO-based therapies, contributed , while such as metabolic and ophthalmic diseases accounted for .
driven by oncology and rare disease treatments. accounted for US$ 32 billion , highlighting their dominance in pipeline development and partnerships. , valued at US$ 13 billion , play a key role in clinical validation and technology innovation.
The U.S., valued at , is the largest market for RNA-based therapies, supported by:
Recent trends in 2025 include and .
Japan's RNA-based therapies market reached and is projected to grow at double-digit rates. Key growth factors include:
In 2025, , reinforcing Japan's leadership in neuromuscular indications.
A leader in ASO-based therapies, Sarepta's revenue from Duchenne muscular dystrophy treatments surpassed
. The company continues to invest heavily in next-gen RNA platforms, including gene-edited RNA therapeutics.
Alnylam dominates the RNAi segment, with products generating . In 2025, the company expanded its ATTR and hypertension portfolio, securing multiple FDA fast-track designations.
Pfizer remains a dominant force in mRNA vaccines, generating from its COVID-19 and pipeline vaccines. The company is actively advancing in partnership with biotech firms.
Moderna reported from its mRNA portfolio, with oncology and rare disease programs leading its post-COVID expansion.
Novartis is strategically investing in RNAi and ASOs, with a growing rare disease pipeline. In 2025, the company partnered with Biogen on RNA-based therapies for neurodegenerative diseases.
The is expected to more than double by 2033, supported by:
1. RNAi Technology Market Size to More Than Double by 2033: Clinical Wins & Delivery Innovations Fuel $6.6B Surge.
2. RNAi Therapeutics Market Size to Surge at 17.4% CAGR Through 2031: Precision Gene Silencing Gains Traction.
3. siRNA Therapeutics Market: Set to Quadruple to US$12.38B by 2033 on Wave of Regulatory Wins & Delivery Breakthroughs.
4. RNA Sequencing Market to Reach New Peaks as NGS & Single-Cell Platforms Fuel $25B Growth by 2034
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter , LinkedIn and Facebook .
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad , Telangana 500039
+1 877-441-4866
Sai.k@datamintelligence.com
https://www.datamintelligence.com/
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/rna-based-therapies-market-to-reach-usd-213-54-billion-by-2033--driven-by-rare-diseases-oncology-and-advances-in-rna-technologies--datam-intelligence-302563110.html